Clinical Trial Update: Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluated the combination of nintedanib with paclitaxel in patients with BRAF wild-type metastatic melanoma; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Malignant Melanoma

Drugs mentioned

• Nintedanib (nintedanib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Prof. Dr. med. Dirk Schadendorf | Conditions: Cutaneous Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED